Simon Mølgaard Named Rising Star in Danish Biotech

We are proud to congratulate Simon Mølgaard, CEO of our portfolio company Teitur Trophics, on being awarded the Rising Star in Danish Biotech at the Biotech Spring Gala — with the recognition displayed on Nasdaq’s iconic screen in Times Square, New York.

This is a testament to Simon’s leadership and the exciting trajectory of Teitur Trophics. We look forward to continuing to support the company on its journey.

Latest news

From a laboratory breakthrough to New York Times Square!

2026.10.222026.10.22 / We are incredibly thrilled to see our recent Series A funding milestone lit up on one of the world's most iconic stages. Seeing our startup's name in the heart of NYC is a powerful reminder of how fa ...

James Breitmeyer, Altay Therapeutics

Eagerly advancing beyond ‘undruggable’ to create novel therapies

2026.10.152026.10.16 / Altay Therapeutics is racing into the clinical stage trials of its first small-molecule inhibitor targeting transcription factors, something many pharmaceutical researchers considered nearly impossib ...

Altay Therapeutics Closes $37 Million Series A Financing to Advance First Oral DUX4 Inhibitor for FSHD into the Clinic

2026.10.152026.10.15 / DX5057 is an orally administered small molecule designed to inhibit DUX4 transcriptional activity and expression of its targeted proteins Clinical program will explore DUX4-related biomarkers and ...